secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019133
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026
----------------------------------------------------------------------------

- Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.
- Cash and equivalents $333.6M; expects to fund operations into 2026.
- TNG908 shows proof-of-mechanism with selective PRMT5 inhibition in MTAP-deleted tumors; no DLTs or grade >2 AEs.
- FDA cleared IND for TNG260 (CoREST inhibitor) and granted Fast Track designation for STK11-mutant NSCLC; phase 1/2 to start 2H 2023.
- Appointed Adam Crystal, M.D., Ph.D., as President of R&D in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/0000950170-23-019133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017023019133/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer